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The relationship between statin use and the risk of
developing Parkinson’s disease (PD) is complex and
remains the subject of debate. Previous epidemiological
studies provide conflicting data, discussed by Jeong and
colleagues in this issue,1 likely attributed, in part, to vari-
ation in study design, but also reflecting the complexity
of the interactions between vascular risk factors, incident
Parkinson’s, and Parkinson’s progression. The reason to
continue to search for clarity is to identify both modifi-
able risk factors and potential neuroprotective agents for
use in prodromal and established disease.
There are strong preclinical data supporting a neuro-
protective effect of statins with regard to disease mecha-
nisms of relevance to PD,2 supporting the rationale for
simvastatin currently being the subject of a phase 2 neu-
roprotective trial.3 The potential protective effects of
statins are also the subject of investigation in other dis-
ease areas, including multiple sclerosis, with a success-
ful phase 2 study4 leading to a current phase 3 trial,5
and previous investigation in Alzheimer’s disease (AD),
with a suggestion of both reduced risk of dementia
development and a slowing of cognitive decline.6
However, for an agent to have efficacy in both PD pre-
vention and progression assumes similarity of disease pro-
cess in both stages of disease—that the “triggers” and
“facilitators” are the same as the “aggravators.”7 We
already have a good illustration in Parkinson’s why this
may be a false assumption: Smoking is protective of inci-
dent PD,8 but once Parkinson’s is diagnosed, smoking
appears to increase the rate of progression.9
The situation is complicated further with regard to sta-
tins because the indication for their initiation (generally
cardiovascular disease) is itself a risk factor for PD devel-
opment, as are associated factors (such as physical inac-
tivity and diabetes). In addition, the therapeutic effect of
statins (lowering of cholesterol) also influences PD risk,
with low cholesterol being associated with a higher risk
of incident PD, a finding which was previously reported10
and is replicated in Jeong’s study.1 The postulated mech-
anisms for this include alteration of lysosomal membrane
stability (which is cholesterol dependent) or reducing
levels of coenzyme Q10. Additionally, higher cholesterol
may be associated with a lower risk of incident PD.
These findings are counterintuitive within the context of
cardiovascular health and risk factors, and tend to con-
flict with our current understanding of the role these play
in the development of neurodegenerative diseases, includ-
ing PD and AD, as well as our understanding of their
role in disease progression.11
Epidemiological studies are fraught with difficulties and
the potential for methodological confounders and biases.
Data ascertainment is typically dependent on insurance
databases which are reliant on accurate clinical diagnosis
and declaration, which in practice may be an under- or
over-representation. Patients may present late, or there
may be diagnostic delay or inaccuracies reflecting health
care provision in different localities. There may be ethnic
differences in the effects of, or response to, statins, with
varying impact of ethnicity on disease progression and
heterogeneity. In addition, prescribing practice relating to
statins has changed significantly over the last 15 years
(the time period covered by most studies) as population
screening and primary prevention have increased.
In this issue of Movement Disorders, Jeong and col-
leagues address several of the important biases using a
data source which covers 97% of the Korean popula-
tion.1 The researchers adjust for a range of risk factors
known to be associated with statin use, including
smoking status, diabetes, hypertension, total choles-
terol, age, and physical activity and demonstrate that
some of these associations with statin use are them-
selves risk factors or associations with PD incidence
(physical activity, smoking, hypertension, coronary
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artery disease, and diabetes). They excluded individuals
with premorbid parkinsonian conditions (another
potential confounder) by incorporating a 4-year run-in
period. The intriguing finding is of short-term (<1 year)
statin use being associated with increased PD risk,
whereas longer-term use is not.
Given the time frame of the association, it is likely
that patients had prodromal PD at the time of statin ini-
tiation. Did the statin “unmask” PD, somehow acting
as an aggravator to speed the progression to clinical
manifestation?
Another possibility is that the process of seeking health
care intervention was triggered by prodromal PD, and
that the outcome of the interaction was a statin prescrip-
tion. We know that health care contacts increase in the
years preceding a Parkinson’s diagnosis, likely reflecting
the accumulation of nonspecific, nonmotor problems.12,13
What has not been explored is the nature of the interac-
tions and consultations that lead to statin prescription in
patients who have a constellation of symptoms and no
clear unifying diagnosis. Might the decision to treat with
a statin be driven by factors other than cardiovascular
risk? What do we know of factors that influence prescrib-
ing practice? What are the relative contributions of clini-
cal protocols, national guidelines, clinician belief, or a
shared understanding of cardiovascular risk? In the study
by Jeong and colleagues, compared to nonusers, statin
users were physically more active, had lower alcohol con-
sumption, were less likely to smoke and had higher house-
hold income, had higher cholesterol and higher blood
pressure, and were twice as likely (43.2% vs. 21.4%) to
have a diagnosis of diabetes, which is associated with a
worse prognosis in established PD. What are the health
care expectations of those with prodromal Parkinson’s
who seek medical advice? It would have been interesting
to know whether those patients who were prescribed sta-
tins were more likely to have symptoms compatible with
prodromal Parkinson’s. Jeong’s well-designed study
addresses some of the important questions relating to sta-
tins and incident Parkinson’s risk, at least in the Korean
population. However, the potential interactions are
indeed complex, possibly too complex for traditional
epidemiological methods of evaluation, and many ques-
tions remain.
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